Focal laser ablation for localized prostate cancer.

Focal laser ablation of prostate cancer: definition, needs, and future. Adv Urol (2012) 0.92

The evolution of lasers in urology. Ther Adv Urol (2011) 0.91

Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol (2014) 0.87

Focal laser ablation of prostate cancer: numerical simulation of temperature and damage distribution. Biomed Eng Online (2011) 0.86

2D Ultrasound and 3D MR Image Registration of the Prostate for Brachytherapy Surgical Navigation. Medicine (Baltimore) (2015) 0.75

Comparison of ablation defect on MR imaging with computer simulation estimated treatment zone following irreversible electroporation of patient prostate. Springerplus (2016) 0.75

Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2010) 6.01

Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41

Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol (2007) 3.12

Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69

Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2013) 2.53

The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol (2002) 2.48

Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23

Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21

Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13

Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst (2012) 2.06

Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88

A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol (2006) 1.71

Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol (2003) 1.70

Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.66

Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. J Urol (2010) 1.63

Long-term outcomes of external sphincterotomy in a spinal injured population. J Urol (2008) 1.57

Clinical significance of the positive surgical margin based upon location, grade, and stage. Urol Oncol (2010) 1.57

Population based survival data on urachal tumors. J Urol (2006) 1.55

Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54

Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol (2006) 1.53

Vulvar hematoma secondary to spontaneous rupture of the internal iliac artery: clinical review. Am J Obstet Gynecol (2009) 1.52

Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int (2014) 1.49

'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int (2009) 1.48

Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47

Metaplastic conditions of the bladder. BJU Int (2013) 1.47

Globalization of continuing professional development by journal clubs via microblogging: a systematic review. J Med Internet Res (2015) 1.44

Physical activity and quality of life after radical prostatectomy. Can Urol Assoc J (2010) 1.44

The emerging use of Twitter by urological journals. BJU Int (2014) 1.42

Renal colic: current protocols for emergency presentations. Eur J Emerg Med (2016) 1.42

Radical prostatectomy in obese patients: Improved surgical outcomes in recent years. Int J Urol (2010) 1.41

Manual bladder washouts for urinary clot retention: a survey of knowledge among healthcare workers. Can J Urol (2015) 1.40

Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res (2009) 1.39

Personal digital assistant data capture: the future of quality of life measurement in prostate cancer treatment. J Oncol Pract (2007) 1.39

A marriage of inconvenience. Med J Aust (2005) 1.39

Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys Med Biol (2009) 1.39

Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med (2006) 1.38

Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology (2010) 1.36

Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35

Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B (2005) 1.34

Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol (2010) 1.33

Sepsis and 'superbugs': should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int (2014) 1.32

Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology (2007) 1.29

Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. Radiology (2008) 1.28

Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer (2011) 1.25

Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol (2010) 1.25

Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care (2003) 1.23

The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. BJU Int (2015) 1.19

The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int (2013) 1.19

Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol (2003) 1.17

Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol (2003) 1.16

Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress. J Urol (2005) 1.14

The social media revolution is changing the conference experience: analytics and trends from eight international meetings. BJU Int (2015) 1.14

Transperineal biopsy of the prostate--is this the future? Nat Rev Urol (2013) 1.14

Transperitoneal laparoscopic prostatectomy does not increase small bowel within the target volume for postoperative radiotherapy. J Urol (2009) 1.13

Organ-sparing approaches for testicular masses. Nat Rev Urol (2010) 1.12

Diagnosis of bone metastases in urological malignancies--an update. Urology (2010) 1.11

Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene (2003) 1.11

Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urol (2005) 1.10

Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. J Clin Epidemiol (2005) 1.09

Gene expression profiling of localized prostate cancer: getting answers to the questions that really matter. J Clin Oncol (2013) 1.08

Photodynamic therapy for urological malignancies: past to current approaches. J Urol (2006) 1.07

Consumerism and its impact on robotic-assisted radical prostatectomy. BJU Int (2011) 1.05

Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. Neoplasia (2007) 1.05

Metachronous metastasis to the penis from carcinoma of the rectum. Int J Urol (2006) 1.05

The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res (2005) 1.02

Changes in health utilities and health-related quality of life over 12 months following radical prostatectomy. Can Urol Assoc J (2009) 1.01

Functional imaging of intratumoral hypoxia. Mol Imaging Biol (2004) 1.01

DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest (2010) 1.01

Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol (2009) 1.00

Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol (2010) 1.00

Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol (2010) 0.99

Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res (2012) 0.98

New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther (2011) 0.98

Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res (2006) 0.98

Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int (2011) 0.98

Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev (2003) 0.98

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol (2010) 0.97

Radical prostatectomy as treatment for prostate cancer. CMAJ (2003) 0.96

Prostate cancer localization with multispectral MRI using cost-sensitive support vector machines and conditional random fields. IEEE Trans Image Process (2010) 0.96

Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology (2009) 0.95

Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nat Rev Urol (2010) 0.94

Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol (2005) 0.94

Serial personal digital assistant data capture of health-related quality of life: a randomized controlled trial in a prostate cancer clinic. Health Qual Life Outcomes (2007) 0.94

Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. Prostate (2005) 0.92

Exploring gay couples' experience with sexual dysfunction after radical prostatectomy: a qualitative study. J Sex Marital Ther (2013) 0.92

Placenta percreta with urinary tract involvement: the case for a multidisciplinary approach. Urology (2009) 0.91

Prevention and management of TURP-related hemorrhage. Nat Rev Urol (2011) 0.90

A randomized trial of aerobic versus resistance exercise in prostate cancer survivors. J Aging Phys Act (2012) 0.90

Penile lichen sclerosus (balanitis xerotica obliterans). BJU Int (2011) 0.90

Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Curr Opin Urol (2009) 0.90

The burden of prostate cancer in Canada. Can Urol Assoc J (2009) 0.90

The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy. Can Urol Assoc J (2009) 0.89

In-bore MRI interventions: current status and future applications. Curr Opin Urol (2015) 0.89

Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? J Urol (2006) 0.89

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther (2003) 0.88